Press Release

Maria Maccecchini to Receive 2011 Iris Newman Award

Berwyn, Pennsylvania - November 7, 2011   More >>>>>

QR Pharma Reports Results from SBIR Grant by NIA/NIH to Study Posiphen® and Metabolites in Various Models

Berwyn, Pennsylvania - October 13, 2011    More >>>>>

QR Pharma to Present Poster at International Conference on Alzheimer's Disease

Berwyn, Pennsylvania - July 12, 2011   More >>>>>

QR Pharma to Present at 10th Annual World Pharma Congress on Parkinson's Disease

Berwyn, Pennsylvania - June 2, 2011   More >>>>>

QR Pharma to Present at 2nd Annual World Congress of NeuroTalk

Radnor, Pennsylvania - May 18, 2011   More >>>>>

QR Pharma to Present at BIO-Windhover Conference/Pharmaceutical Strategic Outlook 2011

Radnor, Pennsylvania - March 31, 2011   More >>>>>

Jeffrey Cummings, Rachelle Doody, Martin Farlow and Mary Sano to Form QR Pharma's Medical Advisory Board

Radnor, Pennsylvania - February 3, 2011   More >>>>>

QR Pharma to Present at the 44th Winter Conference on Brain Research

Radnor, Pennsylvania - January 19, 2011   More >>>>>

QR Pharma receives FDA clearance to conduct clinical trials with its second novel Alzheimer compound, Bisnorcymserine

Radnor, Pennsylvania - December 2, 2010   More >>>>>

QR Pharma Awarded SBIR Grant by NIA/NIH to Test Posiphen® and Metabolites in Various Models

Radnor, Pennsylvania - September 21, 2010   More >>>>>

QR Pharma’s Posiphen® was shown in a Clinical Mechanism of Action Study to Enter the Brain and to Inhibit Amyloid Precursor Protein

Radnor, Pennsylvania - Wednesday, July 14, 2010   More >>>>>

QR Pharma to Present Positive Results of Posiphen® in a Clinical Mechanism of Action Study at the International Congress on Alzheimer's Disease 2010

Radnor, Pennsylvania - Thursday July 1, 2010   More >>>>>

Massachusetts General Hospital and QR Pharma Start a Collaboration on Posiphen® and Parkinson's Disease

Radnor, Pennsylvania - Wednesday, June 16, 2010   More >>>>>

QR Pharma Funding

Radnor, Pennsylvania - Wednesday, June 2, 2010   More >>>>>

QR Pharma to Present on Alzheimer's Disease at the NeuroScienceNetwork

Radnor, Pennsylvania - Thursday, April 29, 2010   More >>>>>

QR Pharma Receives US Patent 7,625,942 to Treat Down Syndrome

Radnor, Pennsylvania - Wednesday, February 24, 2010   More >>>>>

QR Pharma Initiates Clinical Trial for Cognitively Impaired Patients

Radnor, Pennsylvania - Wednesday, February 10, 2010   More >>>>>

Company Taps Region's Proven Experts

Radnor, Pennsylvania - Monday, June 1, 2009   More >>>>>

QR Pharma Receives Seed Investment from Ben Franklin Technology Partners for Further Development of Clinical Stage Compounds to Treat Alzheimer’s Disease

Radnor, Pennsylvania - April 6, 2009  More >>>>>

QR Pharma Inc. Exclusively Licenses Clinical Stage Compounds Posiphen®, Bisnorcymserine and Phenserine to Treat Alzheimer’s Disease

West Chester, Pennsylvania - December 1, 2008    More >>>>>

TorreyPines Therapeutics Licenses Posiphen®, Bisnorcymcerine and Phenserine to QR Pharma

La Jolla, California - November 18, 2008   More >>>>>